ULURU 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	15-May-15
Entity Information [Line Items]
Entity Registrant Name	ULURU Inc.
Entity Central Index Key	1168220
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Common Stock [Member]
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		24,819,534
Series A Preferred Stock [Member]
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		0

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$10,378	$550,458
Accounts receivable, net	3,450	3,879
Accounts receivable - related party, net	978,676	798,147
Inventory	365,804	325,657
Prepaid expenses and deferred charges	78,623	137,858
Total Current Assets	1,436,931	1,815,999
Property, Equipment and Leasehold Improvements, net	373,801	432,110
Other Assets
Intangible assets, net	3,078,528	3,195,689
Investment in unconsolidated subsidiary	0	0
Deposits	18,069	18,069
Total Other Assets	3,096,597	3,213,758
TOTAL ASSETS	4,907,329	5,461,867
Current Liabilities
Accounts payable	1,662,769	1,536,612
Accrued liabilities	259,461	273,201
Deferred revenue, current portion	58,959	58,959
Total Current Liabilities	1,981,189	1,868,772
Long Term Liabilities
Deferred revenue, net of current portion	824,635	839,174
Total Long Term Liabilities	824,635	839,174
TOTAL LIABILITIES	2,805,824	2,707,946
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred stock - $0.001 par value; 20,000 shares authorized; Preferred Stock Series A, 1,000 shares designated; no shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	0	0
Common Stock - $0.001 par value; 200,000,000 shares authorized; 24,458,018 and 24,458,018 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	24,458	24,458
Additional paid-in capital	56,375,739	56,289,882
Accumulated (deficit)	-54,298,692	-53,560,419
TOTAL STOCKHOLDERS' EQUITY	2,101,505	2,753,921
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$4,907,329	$5,461,867

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
STOCKHOLDERS' EQUITY
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	20,000	20,000
Common Stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, shares authorized (in shares)	200,000,000	200,000,000
Common Stock, shares issued (in shares)	24,458,018	24,458,018
Common Stock, shares outstanding (in shares)	24,458,018	24,458,018
Series A Preferred Stock [Member]
STOCKHOLDERS' EQUITY
Shares designated to Series A (in shares)	1,000	1,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenues
License fees	$14,539	$14,539
Royalty income	0	0
Product sales, net	280,109	87,441
Total Revenues	294,648	101,980
Costs and Expenses
Cost of goods sold	101,530	41,042
Research and development	204,159	187,595
Selling, general and administrative	446,157	469,073
Amortization of intangible assets	117,161	117,161
Depreciation	58,309	60,554
Total Costs and Expenses	927,316	875,425
Operating (Loss)	-632,668	-773,445
Other Income (Expense)
Interest and miscellaneous income	142	4,541
Interest expense	-12,969	35,691
Equity in earnings (loss) of unconsolidated subsidiary	0	0
Foreign currency transaction (loss)	-92,778	0
Loss on early extinguishment of convertible note	0	-135,078
(Loss) Before Income Taxes	-738,273	-868,291
Income taxes	0	0
Net (Loss)	-738,273	-868,291
Less preferred stock dividends	0	0
Net (Loss) Allocable to Common Stockholders	($738,273)	($868,291)
Basic and diluted net (loss) per common share (in dollars per share)	($0.03)	($0.04)
Weighted average number of common shares outstanding (in shares)	24,458,018	21,416,265

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
OPERATING ACTIVITIES :
Net loss	($738,273)	($868,291)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of intangible assets	117,161	117,161
Depreciation	58,309	60,554
Share-based compensation for stock and options issued to employees	12,928	4,612
Share-based compensation for options issued to non-employees	62,420	19,928
Equity in earnings (loss) of unconsolidated subsidiary	0	0
Amortization of debt discount on convertible note	0	-81,285
Amortization of deferred financing costs	0	7,309
Warrants issued (cancelled) for services	0	72,771
Common stock issued for services	0	42,600
Common stock issued for interest due on convertible note	0	2,063
Loss on early extinguishment of convertible note	0	135,078
Change in operating assets and liabilities:
Accounts receivable	-180,100	-71,485
Inventory	-40,147	14,638
Prepaid expenses and deferred charges	59,235	-4,031
Notes receivable and accrued interest	0	777,710
Accounts payable	126,157	-310,918
Accrued liabilities	-13,740	-67,146
Accrued interest	0	6,535
Deferred revenue	-14,539	-14,539
Total	187,684	711,555
Net Cash Used in Operating Activities	-550,589	-156,736
INVESTING ACTIVITIES :
Purchase of property and equipment	0	-15,996
Net Cash Used in Investing Activities	0	-15,996
FINANCING ACTIVITIES :
Proceeds from sale of common stock and warrants, net	0	610,000
Proceeds from exercise of common stock warrants	0	1,350,000
Offering cost adjustment - preferred stock sale in 2011	10,509	0
Repayment of principle due on convertible note	0	-776,609
Net Cash Provided by Financing Activities	10,509	1,183,391
Net Increase (Decrease) in Cash	-540,080	1,010,659
Cash, beginning of period	550,458	5,119
Cash, end of period	10,378	1,015,778
SUPPLEMENTAL CASH FLOW DISCLOSURE:
Cash paid for interest	852	983
Non-cash investing and financing activities:
Issuance of common stock for principle due on convertible note	$0	$317,029

COMPANY_OVERVIEW_AND_BASIS_OF_

COMPANY OVERVIEW AND BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2015
COMPANY OVERVIEW AND BASIS OF PRESENTATION [Abstract]
COMPANY OVERVIEW AND BASIS OF PRESENTATION	NOTE 1.	COMPANY OVERVIEW AND BASIS OF PRESENTATION
	Company Overview
	ULURU Inc. (hereinafter “we”, “our”, “us”, “ULURU”, or the “Company”) is a Nevada corporation.  We are a diversified specialty pharmaceutical company committed to developing and commercializing a broad range of innovative wound care and muco-adhesive film products based on our patented Nanoflex® and OraDiscTM technologies, with the goal of improving outcomes for patients, health care professionals, and health care payers.
	Basis of Presentation
	In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and include the accounts of ULURU Inc., a Nevada corporation, and its wholly-owned subsidiary, Uluru Delaware Inc., a Delaware corporation.  They do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position as of March 31, 2015 and the results of its operations for the three months ended March 31, 2015 and 2014 and cash flows for the three months ended March 31, 2015 and 2014 have been made.
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods.  Actual results may differ from those estimates and assumptions.  These differences are usually minor and are included in our consolidated financial statements as soon as they are known.  Our estimates, judgments, and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from those estimates.
	All intercompany transactions and balances have been eliminated in consolidation.
	Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015.
	These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on April 1, 2015, including the risk factors set forth therein.
	Liquidity and Going Concern
	The report of our independent registered public accounting firm for the fiscal year ended December 31, 2014, contained an explanatory paragraph to reflect its significant doubt about our ability to continue as a going concern as a result of our history of losses and our liquidity position, as discussed herein and in this Form 10-Q.  Based on our existing liquidity, the expected level of operating expenses, projected sales of our existing products combined with other revenues and the funding of $500,000 received in April 2015 from the debt financing with Inter-Mountain, we believe that we will be able to meet our working capital and capital expenditure requirements through the second quarter of 2015.  However, we cannot be sure that our anticipated revenue growth will be realized or that we will generate significant positive cash flow from operations.  Moreover, we may not be able to raise sufficient additional capital on acceptable returns, or at all, to continue operations and may not be able to execute any strategic transactions.  Therefore, we are unable to assert that our financial position is sufficient to fund operations beyond the second quarter of 2015, and as a result, there is substantial doubt about our ability to continue as a going concern beyond the second quarter of 2015.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2015
SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2.	SIGNIFICANT ACCOUNTING POLICIES
	The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2015 are consistent with those discussed in Note 2 to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on April 1, 2015.

THE_EFFECT_OF_RECENTLY_ISSUED_

THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS	3 Months Ended
	Mar. 31, 2015
THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS [Abstract]
THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS	NOTE 3.	THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS
	There were no new accounting pronouncements adopted or enacted during the periods presented that had, or are expected to have, a material impact on our financial statements.

SEGMENT_INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Mar. 31, 2015
SEGMENT INFORMATION [Abstract]
SEGMENT INFORMATION	NOTE 4.	SEGMENT INFORMATION
	We operate in one business segment: the research, development and commercialization of pharmaceutical products.  Our corporate headquarters in the United States collects product sales, licensing fees, royalties, and sponsored research revenues from our arrangements with external customers and licensees.  Our entire business is managed by a single management team, which reports to the Chief Executive Officer.
	Our revenues are currently derived primarily from seven licensees for international activities and our domestic sales activities of Altrazeal®.
	Revenues per geographic area for the three months ended March 31 are summarized as follows:
	Revenues		2015				%				2014		%
	Domestic		$	6,802				2	%		$	9,672		9	%
	International			287,846				98	%			92,308		91	%
	Total		$	294,648				100	%		$	101,980		100	%
	A significant portion of our revenues are derived from a few major customers.  Customers with greater than 10% of total revenues for the three months ended March 31 are represented on the following table:
	Customers	Product		2015				2014
	Customer A	Altrazeal®			93	%			1	%
	Customer B	Altrazeal®			2	%			81	%
	Total				95	%			82	%

INVENTORY

INVENTORY	3 Months Ended
	Mar. 31, 2015
INVENTORY [Abstract]
INVENTORY	NOTE 5.	INVENTORY
	As of March 31, 2015, our inventory was comprised of Altrazeal® finished goods, manufacturing costs incurred in the production of Altrazeal®, and raw materials.  Inventories are stated at the lower of cost (first in, first out method) or market.  We regularly review inventories on hand and write down the carrying value of our inventories for excess and potentially obsolete inventories based on historical usage and estimated future usage.  In assessing the ultimate realization of our inventories, we are required to make judgments as to future demand requirements.  As actual future demand or market conditions may vary from those projected by us, adjustment to inventories may be required.
	The components of inventory, at the different stages of production, consisted of the following at March 31, 2015 and December 31, 2014:
	Inventory		31-Mar-15		31-Dec-14
	Raw materials		$	43,633	$	41,648
	Work-in-progress			310,648		271,571
	Finished goods			11,523		12,438
	Total		$	365,804	$	325,657

PROPERTY_EQUIPMENT_and_LEASEHO

PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS	3 Months Ended
	Mar. 31, 2015
PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS [Abstract]
PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS	NOTE 6.	PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS
	Property, equipment and leasehold improvements, net, consisted of the following at March 31, 2015 and December 31, 2014:
	Property, equipment and leasehold improvements		31-Mar-15			31-Dec-14
	Laboratory equipment		$	424,888		$	424,888
	Manufacturing equipment			1,599,894			1,599,894
	Computers, office equipment, and furniture			153,078			153,078
	Computer software			4,108			4,108
	Leasehold improvements			95,841			95,841
				2,277,809			2,277,809
	Less: accumulated depreciation and amortization			(1,904,008	)		(1,845,699	)
	Property, equipment and leasehold improvements, net		$	373,801		$	432,110
	Depreciation expense on property, equipment and leasehold improvements was $58,309 and $60,554 for the three months ended March 31, 2015 and 2014, respectively.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2015
INTANGIBLE ASSETS [Abstract]
INTANGIBLE ASSETS	NOTE 7.	INTANGIBLE ASSETS
	Intangible assets are comprised of patents acquired in October, 2005.  Intangible assets, net consisted of the following at March 31, 2015 and December 31, 2014:
	Intangible assets		31-Mar-15			31-Dec-14
	Patent - Amlexanox (Aphthasol®)		$	2,090,000		$	2,090,000
	Patent - Amlexanox (OraDisc™ A)			6,873,080			6,873,080
	Patent - OraDisc™			73,000			73,000
	Patent - Hydrogel nanoparticle aggregate			589,858			589,858
				9,625,938			9,625,938
	Less: accumulated amortization			( 6,547,410	)		(6,430,249	)
	Intangible assets, net		$	3,078,528		$	3,195,689
	Amortization expense for intangible assets was $117,161 and $117,161 for the three months ended March 31, 2015 and 2014, respectively.
	The future aggregate amortization expense for intangible assets, remaining as of March 31, 2015, is as follows:
	Calendar Years		Future Amortization
			Expense
	2015 (Nine months)		$	357,987
	2016			476,450
	2017			475,148
	2018			475,148
	2019			475,148
	2020 & Beyond			818,647
	Total		$	3,078,528

INVESTMENTS_IN_UNCONSOLIDATED_

INVESTMENTS IN UNCONSOLIDATED ENTITIES	3 Months Ended
	Mar. 31, 2015
INVESTMENTS IN UNCONSOLIDATED ENTITIES [Abstract]
INVESTMENTS IN UNCONSOLIDATED ENTITIES	NOTE 8.	INVESTMENTS IN UNCONSOLIDATED ENTITIES
	We use the equity method of accounting for investments in other companies that are not controlled by us and in which our interest is generally between 20% and 50% of the voting shares or we have significant influence over the entity, or both.
	Altrazeal Trading Ltd.
	On January 11, 2012, we executed a shareholders’ agreement for the establishment of Altrazeal Trading Ltd., a single purpose entity to be used for the exclusive marketing of Altrazeal® throughout the European Union, Australia, New Zealand, North Africa, and the Middle East.  As a result of this transaction, we received a non-dilutable 25% ownership interest in Altrazeal Trading Ltd.  On February 1, 2014, Altrazeal Trading Ltd. transferred all of their rights and obligations under the existing shareholders’ agreement to Altrazeal Trading GmbH.
	Audited financial statements of Altrazeal Trading Ltd. for the years ended December 31, 2013 and 2014 and unaudited financial statements for the three months ended March 31, 2015 have not been released to us and, therefore, we have not included the effect of the financial activities of Altrazeal Trading Ltd. in our financial statements for each reporting period.  We believe that our share of the cumulative losses of Altrazeal Trading Ltd. for the three months ended March 31, 2015 and for the years ended December 31, 2014, 2013, and 2012 would exceed the carrying value of our investment, therefore the equity method of accounting would be suspended for such reporting periods and no additional losses would be charged to operations.
	Based upon audited financial statements received in May 2014, our unrecorded share of Altrazeal Trading Ltd. losses for the year ended December 31, 2012 totaled $129,207.
	Summarized financial information for our investment in Altrazeal Trading Ltd. assuming 100% ownership is as follows:
	Altrazeal Trading Ltd.		31-Dec-12
	Balance sheet
	Total assets		$	136,661
	Total liabilities		$	660,006
	Total stockholders’ (deficit)		$	(523,345	)
	Statement of operations
	Revenues		$	61,028
	Net (loss)		$	(516,829	)
	Altrazeal Trading GmbH
	On February 1, 2014, Altrazeal Trading Ltd. transferred all of their rights and obligations under the existing shareholders’ agreement to Altrazeal Trading GmbH.  As a result of this transfer, we received a non-dilutable 25% ownership interest in Altrazeal Trading GmbH.
	Audited financial statements of Altrazeal Trading GmbH for the years ended December 31, 2013 and 2014 and unaudited financial statements for the three months ended March 31, 2015 have not been released to us and, therefore, we have not included the effect of the financial activities of Altrazeal Trading GmbH in our financial statements for each reporting period.  We believe that our share of the cumulative losses of Altrazeal Trading GmbH for the three months ended March 31, 2015 and for the years ended December 31, 2014 and 2013 would exceed the carrying value of our investment, therefore the equity method of accounting would be suspended for such reporting periods and no additional losses would be charged to operations.
	Based upon the unaudited financial statements for the year ended December 31, 2013, our unrecorded share of Altrazeal Trading GmbH cumulative losses as of December 31, 2013 totaled $213,370.
	Summarized financial information for our investment in Altrazeal Trading GmbH assuming 100% ownership is as follows:
	Altrazeal Trading GmbH		31-Dec-13
			(Unaudited)
	Balance sheet
	Total assets		$	757,784
	Total liabilities		$	1,563,046
	Total stockholders’ (deficit)		$	(805,262	)
	Statement of operations
	Revenues		$	---
	Net (loss)		$	(798,009	)
	ORADISC GmbH
	On October 19, 2012, we executed a shareholders’ agreement for the establishment of ORADISC GmbH, a single purpose entity to be used for the exclusive development and marketing of OraDisc™ erodible film technology products.  We received a non-dilutable 25% ownership interest in ORADISC GmbH.
	Audited financial statements of ORADISC GmbH for the years ended December 31, 2013 and 2014 and unaudited financial statements for the three months ended March 31, 2015 have not been released to us and, therefore, we have not included the effect of the financial activities of ORADISC GmbH. in our financial statements for each reporting period.  We believe that our share of the cumulative losses of ORADISC GmbH for the three months ended March 31, 2015 and for the years ended December 31, 2014 and 2013 would exceed the carrying value of our investment, therefore the equity method of accounting would be suspended for such reporting periods and no additional losses would be charged to operations.
	Based upon the unaudited financial statements for the year ended December 31, 2013, our unrecorded share of ORADISC GmbH cumulative losses as of December 31, 2013 totaled $11,430.
	Summarized financial information for our investment in ORADISC GmbH assuming 100% ownership is as follows:
	ORADISC GmbH		31-Dec-13
			(Unaudited)
	Balance sheet
	Total assets		$	305,069
	Total liabilities		$	302,572
	Total stockholders’ equity		$	2,497
	Statement of operations
	Revenues		$	---
	Net (loss)		$	(34,671	)
	Altrazeal AG
	On February 1, 2014, we executed a shareholders’ agreement with Altrazeal AG, a single purpose entity for the marketing of Altrazeal® in several territories, including Africa (markets not already licensed), Latin America, Georgia, Turkmenistan, Ukraine, the Commonwealth of Independent States, Jordan, Syria, Asia and the Pacific (excluding China, Hong Kong, Macau, Taiwan, South Korea, Japan, Australia, and New Zealand).  As a result of this transaction, we received a non-dilutable 25% ownership interest in Altrazeal AG.
	Audited or unaudited financial statements of Altrazeal AG for the three months ended March 31, 2015 and for the year ended December 31, 2014 have not been released to us and, therefore, we have not included the effect of the financial activities of Altrazeal AG in our financial statements for such reporting period.  We believe that our share of the cumulative losses of Altrazeal AG for the three months ended March 31, 2015 and for the year ended December 31, 2014 would exceed the carrying value of our investment, therefore the equity method of accounting would be suspended for such reporting periods and no additional losses would be charged to operations.

ACCRUED_LIABILITIES

ACCRUED LIABILITIES	3 Months Ended
	Mar. 31, 2015
ACCRUED LIABILITIES [Abstract]
ACCRUED LIABILITIES	NOTE  9.	ACCRUED LIABILITIES
	Accrued liabilities consisted of the following at March 31, 2015 and December 31, 2014:
	Accrued Liabilities		31-Mar-15		31-Dec-14
	Accrued taxes – payroll		$	106,299	$	106,299
	Accrued compensation/benefits			123,887		96,795
	Accrued insurance payable			26,270		69,815
	Accrued property taxes			3,000		---
	Product rebates/returns			5		13
	Other			---		279
	Total accrued liabilities		$	259,461	$	273,201

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2015
STOCKHOLDERS' EQUITY [Abstract]
STOCKHOLDERS' EQUITY	NOTE 10.	STOCKHOLDERS’ EQUITY
	Common Stock
	As of March 31, 2015, we had 24,458,018 shares of Common Stock issued and outstanding.  For the three months ended March 31, 2015, we did not issue any Common Stock.
	Preferred Stock
	As of March 31, 2015, we had no shares of Series A Preferred Stock (the “Series A Shares”) issued and outstanding.  For the three months ended March 31, 2015, we did not issue or redeem any Series A Shares.
	Warrants
	The following table summarizes the warrants outstanding and the number of shares of Common Stock subject to exercise as of March 31, 2015 and the changes therein during the three months then ended:
			Number of Shares of Common Stock Subject to Exercise			Weighted – Average
						Exercise Price
	Balance as of December 31, 2014			1,676,401		$	1.14
	Warrants issued (1)			(31,341	)	$	0.35
	Warrants exercised			---			---
	Warrants cancelled			---			---
	Balance as of March 31, 2015			1,645,060		$	1.15
	-1	As part of the June 2012 Note, Inter-Mountain received a total of seven warrants to purchase, if they all had vested, an aggregate of 3,142,857 shares of Common Stock, which number of shares could increase based upon the terms and conditions of the warrants.  The warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017.  Warrants for 785,714, 392,857, 392,857, and 392,857 shares of Common Stock vested on June 27, 2012, December 31, 2012, February 26, 2013, and July 15, 2013, respectively, and three warrants for 1,571,428 shares of Common Stock were exercised in 2013.  On January 22, 2014, we elected to offset and deduct the three remaining Investor Notes from the principle amount due to Inter-Mountain under the June 2012 Note and as a result of the offset and deduction the three remaining warrants terminated.  On April 14, 2015, we reached agreement with Inter-Mountain that 361,516 shares of Common Stock will be issued upon the exercise of the one unexercised warrant (originally included in this Table as 392,857 shares, which was based upon an exercise price of $0.35 per share of Common Stock).
	For the three months ended March 31, 2015, we did not issue any new warrants.
	Of the warrant shares subject to exercise as of March 31, 2015, expiration of the right to exercise is as follows:
	Date of Expiration		Number of Warrant Shares of Common Stock Subject to Expiration
	May 15, 2015			357,155
	June 13, 2016			35,000
	July 16, 2016			116,667
	July 28, 2016			34,722
	June 27, 2017			361,516
	March 14, 2018			660,000
	January 15, 2019			80,000
	Total			1,645,060

EARNINGS_PER_SHARE

EARNINGS PER SHARE	3 Months Ended
	Mar. 31, 2015
EARNINGS PER SHARE [Abstract]
EARNINGS PER SHARE	NOTE 11.	EARNINGS PER SHARE
	Basic and Diluted Net Loss Per Share
	In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 260, Earnings per Share, basic earnings (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period.  Diluted earnings (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period, increased to include potential dilutive common shares.  The effect of outstanding stock options, restricted vesting Common Stock, convertible debt, convertible preferred stock, and warrants, when dilutive, is reflected in diluted earnings (loss) per common share by application of the treasury stock method.  We have excluded all outstanding stock options, restricted vesting Common Stock, convertible debt, convertible preferred stock, and warrants from the calculation of diluted net loss per common share because all such securities are antidilutive for all periods presented.
	Shares used in calculating basic and diluted net loss per common share exclude these potential common shares as of March 31, 2015 and December 31, 2014:
			31-Mar-15		31-Dec-14
	Warrants to purchase Common Stock			1,645,060		1,676,401
	Stock options to purchase common stock			1,699,907		1,699,907
	Total			3,344,967		3,376,308

SHARE_BASED_COMPENSATION

SHARE BASED COMPENSATION	3 Months Ended
	Mar. 31, 2015
SHARE BASED COMPENSATION [Abstract]
SHARE BASED COMPENSATION	NOTE 12.	SHARE BASED COMPENSATION
	The Company’s share-based compensation plan, the 2006 Equity Incentive Plan, as amended (“Equity Incentive Plan”), is administered by the compensation committee of the Board of Directors (“Board”), which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the award.
	Our Board granted the following incentive stock option awards to executives or employees and nonstatutory stock option awards to directors or non-employees for the three months ended March 31:
			Three Months Ended March 31,
			2015 (1)				2014 (1)
	Incentive Stock Options
	Quantity			---				---
	Weighted average fair value per share			---				---
	Fair value			---				---
	Nonstatutory Stock Options
	Quantity			---				---
	Weighted average fair value per share			---				---
	Fair value			---				---
	-1	The Company did not award any shared-based compensation for the three months ended March 31, 2015 and 2014.
	We account for share-based compensation under FASB ASC Topic 718, Stock Compensation, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values of the award on the grant date.  We use the Black-Scholes option-pricing model to estimate the fair value of share-based awards.
	Stock Options (Incentive and Nonstatutory)
	The following table summarizes share-based compensation related to stock options for the three months ended March 31:
			Three Months Ended
			March 31,
			2015				2014
	Research and development		$	18,612			$	5,307
	Selling, general and administrative			56,736				19,233
	Total share-based compensation expense		$	75,348			$	24,540
	At March 31, 2015, the balance of unearned share-based compensation to be expensed in future periods related to unvested stock option awards, as adjusted for expected forfeitures, is approximately $482,000.  The period over which the unearned share-based compensation is expected to be recognized is approximately thirty months.
	The following table summarizes the stock options outstanding and the number of shares of Common Stock subject to exercise as of March 31, 2015 and the changes therein during the three months then ended:
			Stock Options				Weighted Average Exercise Price per Share
	Outstanding as of December 31, 2014			1,699,907			$	1.73
	Granted			---				---
	Forfeited/cancelled			---				---
	Exercised			---				---
	Outstanding as of March 31, 2015			1,699,907			$	1.73
	The following table presents the stock option grants outstanding and exercisable as of March 31, 2015:
	Options Outstanding										Options Exercisable
	Stock Options Outstanding				Weighted Average Exercise Price per Share				Weighted Average Remaining Contractual Life in Years		Stock Options Exercisable		Weighted Average Exercise Price per Share
		892,500			$	0.33				8		645,000	$	0.33
		685,000				1.15				7.7		77,500		1.15
		53,334				2.38				3.2		53,334		2.38
		69,073				25.12				2.3		69,073		25.12
		1,699,907			$	1.73				7.5		844,907	$	2.56
	Restricted Stock Awards
	Restricted stock awards, which typically vest over a period of two to five years, are issued to certain key employees and are subject to forfeiture until the end of an established restriction period.  We utilize the market price on the date of grant as the fair market value of restricted stock awards and expense the fair value on a straight-line basis over the vesting period.
	For the three months ended March 31, 2015 and 2014, we did not grant any restricted stock awards.
	Summary of Plans
	2006 Equity Incentive Plan
	In March 2006, our Board adopted and our stockholders approved our Equity Incentive Plan, which initially provided for the issuance of up to 133,333 shares of our Common Stock pursuant to stock option and other equity awards.  At the annual meetings of the stockholders held on May 8, 2007, December 17, 2009, June 15, 2010, June 14, 2012, June 13, 2013, and on June 5, 2014, our stockholders approved amendments to the Equity Incentive Plan to increase the total number of shares of Common Stock issuable under the Equity Incentive Plan pursuant to stock options and other equity awards by 266,667 shares, 200,000 shares, 200,000 shares, 400,000 shares, 600,000 shares, and 1,000,000 shares, respectively, to a total of 2,800,000 shares.
	In December 2006, we began issuing stock options to employees, consultants, and directors.  The stock options issued generally vest over a period of one to four years and have a maximum contractual term of ten years.  In January 2007, we began issuing restricted stock awards to our employees.  Restricted stock awards generally vest over a period of six months to five years after the date of grant.  Prior to vesting, restricted stock awards do not have dividend equivalent rights, do not have voting rights and the shares underlying the restricted stock awards are not considered issued and outstanding.  Shares of Common Stock are issued on the date the restricted stock awards vest.
	As of March 31, 2015, we had granted options to purchase 2,061,167 shares of Common Stock since the inception of the Equity Incentive Plan, of which 1,699,907 were outstanding at a weighted average exercise price of $1.73 per share, and we had granted awards for 68,616 shares of restricted stock since the inception of the Equity Incentive Plan, of which none were outstanding.  As of March 31, 2015, there were 1,030,647 shares that remained available for future grants under our Equity Incentive Plan.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2015
FAIR VALUE MEASUREMENTS [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 13.	FAIR VALUE MEASUREMENTS
	In accordance with FASB ASC Topic 820, Fair Value Measurements, (“ASC Topic 820”) certain assets and liabilities of the Company are required to be recorded at fair value.  Fair value is determined based on the exchange price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants.  The guidance in ASC Topic 820 also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimized the use of unobservable inputs by requiring that the most observable inputs be used when available.
	Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on our market assumptions.  Unobservable inputs require significant management judgment or estimation.  In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy.  In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement.  Such determination requires significant management judgment.
	The three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies, is as follows:
		Level 1	—	Valuations based on quoted prices (unadjusted) for identical assets or liabilities in active markets.
		Level 2	—	Valuations based on observable inputs other than quoted prices in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and other inputs that are observable or can be corroborated by observable market data.
		Level 3	—	Valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants.
	Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurements.  We review the fair value hierarchy classification on a quarterly basis.  Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.
	Our financial instruments, including cash, cash equivalents, accounts receivable, and accounts payable are carried at cost, which approximates their fair value because of the short-term maturity of these instruments.  We believe that the carrying value of our other receivable and convertible note payable balances approximates fair value based on a valuation methodology using the income approach and a discounted cash flow model.

INCOME_TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2015
INCOME TAXES [Abstract]
INCOME TAXES	NOTE 14.	INCOME TAXES
	There was no current federal tax provision or benefit recorded for any period since inception, nor were there any recorded deferred income tax assets, as such amounts were completely offset by valuation allowances.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2015
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 15.	COMMITMENTS AND CONTINGENCIES
	Operating Leases
	On January 31, 2006 we entered into a lease agreement for office and laboratory space in Addison, Texas.  The lease commenced on April 1, 2006 and originally continued until April 1, 2013.  The lease required a minimum monthly lease obligation of $9,330, which was inclusive of monthly operating expenses, until April 1, 2011 and at such time increased to $9,776, which was inclusive of monthly operating expenses.  On February 22, 2013, we executed an Amendment to Lease Agreement (the “Lease Amendment”) that renewed and extended our lease until March 31, 2015.  The Lease Amendment required a minimum monthly lease obligation of $9,193, which was inclusive of monthly operating expenses, until March 31, 2014 and at such time, increased to $9,379, which was inclusive of monthly operating expenses.  On March 17, 2015, we executed a Second Amendment to Lease Agreement (the “Second Amendment”) that renewed and extended our lease until March 31, 2018.  The Second Amendment requires a minimum monthly lease obligation of $9,436, which is inclusive of monthly operating expenses.
	On December 10, 2010 we entered into a lease agreement for certain office equipment that commenced on February 1, 2011 and continued until February 1, 2015 and required a minimum lease obligation of $744 per month.  On January 16, 2015 we entered into a new lease agreement for certain office equipment.  The new office equipment lease, that commenced on February 1, 2015 and continues until February 1, 2018, requires a minimum lease obligation of $551 per month.
	The future minimum lease payments under the 2015 office lease and the 2015 equipment lease are as follows as of March 31, 2015:
	Calendar Years		Future Lease Expense
	2015 (Nine months)		$	89,880
	2016			119,840
	2017			119,840
	2018			28,858
	2019			---
	Total		$	358,418
	Rent expense for our operating leases amounted to $31,165 and $30,380 for the three ended March 31, 2015 and 2014, respectively.
	Indemnification
	In the normal course of business, we enter into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. Our exposure under these agreements is unknown because it involves claims that may be made against us in the future, but have not yet been made. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. However, we may record charges in the future as a result of these indemnification obligations.
	In accordance with our restated articles of incorporation and our amended and restated bylaws, we have indemnification obligations to our officers and directors for certain events or occurrences, subject to certain limits, while they are serving at our request in their respective capacities. There have been no claims to date and we have a director and officer insurance policy that enables us to recover a portion of any amounts paid for future potential claims. We have also entered into contractual indemnification agreements with each of our officers and directors.
	Related Party Transactions and Concentration
	On January 17, 2013, the Board of Directors of the Company appointed Helmut Kerschbaumer and Klaus Kuehne to each serve as a director of the Company.
	Mr. Kerschbaumer currently serves as a director of Altrazeal Trading GmbH, Altrazeal AG, and Melmed Holding AG (collectively, the “Altrazeal Distributors”) and Mr. Kuehne currently serves as a director of Altrazeal AG.  In such capacities, Mr. Kerschbaumer may be considered, either singularly or collectively, to have control of, and make investment and business decisions on behalf of the Altrazeal Distributors and Mr. Kuehne may be considered, either singularly of collectively, to have control of, and make investment and business decisions on behalf of Altrazeal AG.
	Each of Mr. Kerschbaumer and Mr. Kuehne are shareholders of ORADISC GmbH and may be considered, either singularly or collectively, to have control of, and make investment and business decisions on behalf of the ORADISC GmbH.
	Currently, we are party to License and Supply Agreements with Altrazeal Trading GmbH, Altrazeal AG, and Melmed Holding AG for the marketing and distribution of Altrazeal in various international territories.  We are also party to a License and Supply Agreement with ORADISC GmbH for the marketing of all applications of our OraDisc™ erodible film technology for dental applications including benzocaine (OraDisc™ B), re-mineralization dental strips, fluoride dental strips, long-acting breath freshener, amlexanox (OraDisc™ A) in certain territories, anti-psychotics, neurologic products, and actives for the treatment of erectile dysfunction.
	For the three months ended March 31, 2015 and 2014, the Company recorded revenues, in approximate numbers, of $282,000 and $86,000, respectively, with the various Altrazeal Distributors, which represented 96% and 84% of our total revenues.  As of March 31, 2015 and December 31, 2014, Altrazeal Distributors had an outstanding net accounts receivable, in approximate numbers, of $979,000 and $798,000, respectively, which represented 99.7% and 99.5% of our total outstanding accounts receivables.
	Related Party Obligations
	Since 2011, our named executive officers and certain key executives have temporarily deferred portions of their compensation as part of a plan to conserve the Company’s cash and financial resources.
	As of March 31, 2015, the following table summarizes the compensation temporarily deferred and subsequent repayments:
	Name		2015		2014			2013			2012		2011		Total
	Kerry P. Gray (1) (2) (3)		$	57,575	$	(119,986	)	$	(91,000	)	$	220,673	$	140,313	$	207,575
	Terrance K. Wallberg			6,633		(25,000	)		(35,769	)		24,230		36,539		6,633
	Total		$	64,208	$	(144,986	)	$	(126,769	)	$	244,903	$	176,852	$	214,208
		-1	During 2015, Mr. Gray temporarily deferred compensation of $57,575 which consisted of $5,075 earned as salary compensation for his duties as President of the Company and $52,500 for his duties as Chairman of the Executive Committee of the Company’s Board of Directors.
		-2	During 2014, Mr. Gray temporarily deferred compensation of $150,000 which consisted of $62,500 earned as salary compensation for his duties as President of the Company and $87,500 for his duties as Chairman of the Executive Committee of the Company’s Board of Directors.  During 2014, Mr. Gray was also repaid $269,986 of temporarily deferred compensation, of which $100,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.
		-3	During 2013, Mr. Gray temporarily deferred compensation of $221,500 which consisted of $11,500 earned pursuant to a Separation Agreement and $210,000 for his duties as Chairman of the Executive Committee of the Company’s Board of Directors.  During 2013, Mr. Gray was also repaid $312,500 of temporarily deferred compensation, of which $300,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.
	As of March 31, 2015, the Company’s obligation for temporarily deferred compensation was $214,208 of which $74,208 was included in accrued liabilities and $140,000 was included in accounts payable, respectively.
	As of December 31, 2014, the Company’s obligation for temporarily deferred compensation was $150,000 of which $62,500 was included in accrued liabilities and $87,500 was included in accounts payable, respectively.
	Contingent Milestone Obligations
	We are subject to paying Access Pharmaceuticals, Inc. (“Access”) for certain milestones based on our achievement of certain annual net sales, cumulative net sales, and/or our having reached certain defined technology milestones including licensing agreements and advancing products to clinical development.  As of March 31, 2015, the future milestone obligations that we are subject to paying Access, if the milestones related thereto are achieved, total $4,750,000.  Such milestones are based on total annual sales of 20 and 40 million dollars of certain products, annual sales of 20 million dollars of any one certain product, and cumulative sales of such products of 50 and 100 million dollars.
	On March 7, 2008, we terminated the license agreement with ProStrakan Ltd. for Amlexanox-related products in the United Kingdom and Ireland.  As part of the termination, we agreed to pay ProStrakan Ltd. a royalty of 30% on any future payments received by us from a new licensee in the United Kingdom and Ireland territories, up to a maximum of $1,400,000.  On November 17, 2008, we entered into a licensing agreement for Amlexanox-related product rights to the United Kingdom and Ireland territories with MEDA AB.

LEGAL_PROCEEDINGS

LEGAL PROCEEDINGS	3 Months Ended
	Mar. 31, 2015
LEGAL PROCEEDINGS [Abstract]
LEGAL PROCEEDINGS	NOTE 16.	LEGAL PROCEEDINGS
	On or about August 22, 2014, Inter-Mountain Capital Corp. (“Inter-Mountain”) filed a Complaint against ULURU in the U.S. Federal Court for the District of Utah, Central Division.  The Complaint relates to Inter-Mountain’s delivery of a notice of a cashless exercise with respect to its last remaining warrant to purchase Common Stock on or about May 1, 2014 purporting to exercise it with respect to the delivery of 782,284 shares of Common Stock under the non-standard cashless exercise or conversion provisions in the warrant.  The Company declined to honor the exercise on the basis that, as a result of an amendment to the warrant agreed to in December 2013, the warrant was exercisable, on a cashless basis, with respect to only 261,516 shares of Common Stock as of May 1, 2014.  Inter-Mountain alleged that the Company’s refusal to honor the exercise constituted a breach of the warrant, breach of implied covenant of good faith and fair dealing, unjust enrichment, a violation of securities laws and common law fraud and sought actual damages, consequential damages, treble damages, specific performance, attorneys’ fees and costs and other relief.  Answers and counterclaims were filed.
	On April 15, 2015, the Company and Inter-Mountain entered into a Settlement Agreement (the “Settlement Agreement”) for the purpose of settling the pending litigation between the Company and Inter-Mountain.  Under the Settlement Agreement and related documents, the Company and Inter-Mountain agreed that Inter-Mountain would exercise the warrant and receive 361,516 shares of Common Stock.  The Settlement Agreement also included standard releases and anticipated the prompt filing of dismissal documents.  As part of the settlement, the Company and Inter-Mountain signed and closed under the Securities Purchase Agreement described in Note 17.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2015
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	NOTE 17.	SUBSEQUENT EVENTS
	Debt Financing – April 2015
	On April 15, 2015, we entered into a Securities Purchase Agreement dated April 14, 2015 (the “Purchase Agreement”) with Inter-Mountain related to our issuance of a $550,000 Promissory Note (the “Note”).  The purchase price for the Note, which reflects a $50,000 original issue discount, was $500,000. The Purchase Agreement also includes representations and warranties, restrictive covenants and indemnification provisions standard for similar transactions.
	The Note bears interest at the rate of 10.0% per annum, with monthly installment payments of $45,000 commencing on the date that is 120 calendar days after the issuance date of the Note. At our option, subject to certain volume, price and other conditions, the monthly installments may be paid in whole, or in part, in cash or in common stock, $0.001 par value, of Uluru (“Common Stock”).  If the monthly installments are paid in Common Stock, such shares being issued will be based on a price that is 80% of the average of the three lowest volume weighted average prices of the shares of Common Stock during the preceding twenty trading days.  The percentage declines to 70% if the average of the three lowest volume weighted average prices of the shares of Common Stock during the preceding twenty trading days is less than $0.05 per share.  The Note is not subject to conversion at the discretion of Inter-Mountain.
	At our option, the outstanding principal balance of the Note, or a portion thereof, may be prepaid in cash at 120% of the amount elected to be prepaid.  The Note is unsecured.
	Events of default under the Note include failure to make required payments, the entry of a $100,000 judgment not stayed within 30 days, breach of representations or covenants under the transaction documents, various events associated with insolvency or failure to pay debts, delisting of the Common Stock, a restatement of financial statements and a default under certain other agreements.  In the event of default, the interest rate under the Note increases to 18% and the Note becomes callable at a premium.  In addition, Inter-Mountain has all remedies under law and equity.
	As part of the debt financing, Inter-Mountain also received a warrant (the “Warrant”) to purchase up to an aggregate of 194,118 shares of Common Stock.  The Warrant has an exercise price of $0.85 per share and expires on April 30, 2020. The Warrant includes a standard net cashless exercise provision and provisions requiring proportionate adjustments in connection with a recapitalization transaction.
	As part of the debt financing, we entered into a Registration Rights Agreement whereby we have agreed to prepare and file with the Securities and Exchange Commission a registration statement no later than May 11, 2015 and to cause such registration statement to be declared effective no later than 120 after the closing date and to keep such registration statement effective for a period of no less than 180 days.
	In connection with the Purchase Agreement, the Company and Inter-Mountain entered into the Settlement Agreement described in Note 16.
	Purchase of Altrazeal Trading, GmbH – May 2015
	On May 12, 2015, we entered into a Binding Term Sheet (the “Term Sheet”) with IPMD GmbH, an Austrian limited liability company, and Firnron Ltd., a Cypriot limited liability company (collectively, the “Seller”) related to our purchase of 75% of the share capital of Altrazeal Trading GmbH, an Austrian limited liability company (“Altrazeal Trading”).  Uluru currently owns the remaining 25% of share capital of Altrazeal Trading.  Altrazeal Trading is the distributor of Altrazeal® transforming powder dressing in European Union, Australia, New Zealand, Middle East (excluding Jordan and Syria), North Africa, Albania, Bosnia, Croatia, Kosovo, Macedonia, Montenegro, and Serbia.
	The purchase price is composed of 3,150,000 Euro for the purchase of the share capital of Altrazeal Trading and 88,834 Euro for the purchase of product inventory.  The purchase of the share capital of Altrazeal Trading will be paid in installments, with 1,147,200 Euro due at closing (of which 646,500 Euro will be paid with an offset of accounts receivable) and four installment payments of 500,700 Euro due by no later than June 30, 2015, August 31, 2015, October 31, 2015, and December 31, 2015.  The sale is structured as an “installment sale”, with 15% of equity in Altrazeal Trading being transferred upon the payment of each installment by us.  The installments are payable in either cash or in shares of our common stock at our option.  If installment payments are made in common stock, the calculation of shares to be issued will be 110% of the average closing price for the last 10 trading days prior to the installment payment date and include a warrant for 10% of the shares issued with a premium of $0.30 per share to the market price. The purchase of the product inventory for 88,834 Euro will be paid on September 30, 2015.
	To the extent we issue shares of common stock to pay the purchase price, we have agreed to register the resale of such shares to the extent possible. The Term Sheet anticipates the negotiation and execution of a purchase agreement containing all terms of the Term Sheet and other standard terms for such a transaction within 60 days.

COMPANY_OVERVIEW_AND_BASIS_OF_1

COMPANY OVERVIEW AND BASIS OF PRESENTATION (Policies)	3 Months Ended
	Mar. 31, 2015
COMPANY OVERVIEW AND BASIS OF PRESENTATION [Abstract]
Basis of Presentation	Basis of Presentation
	In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and include the accounts of ULURU Inc., a Nevada corporation, and its wholly-owned subsidiary, Uluru Delaware Inc., a Delaware corporation.  They do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position as of March 31, 2015 and the results of its operations for the three months ended March 31, 2015 and 2014 and cash flows for the three months ended March 31, 2015 and 2014 have been made.
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods.  Actual results may differ from those estimates and assumptions.  These differences are usually minor and are included in our consolidated financial statements as soon as they are known.  Our estimates, judgments, and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from those estimates.
	All intercompany transactions and balances have been eliminated in consolidation.
	Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015.
	These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on April 1, 2015, including the risk factors set forth therein.
Liquidity and Going Concern	Liquidity and Going Concern
	The report of our independent registered public accounting firm for the fiscal year ended December 31, 2014, contained an explanatory paragraph to reflect its significant doubt about our ability to continue as a going concern as a result of our history of losses and our liquidity position, as discussed herein and in this Form 10-Q.  Based on our existing liquidity, the expected level of operating expenses, projected sales of our existing products combined with other revenues and the funding of $500,000 received in April 2015 from the debt financing with Inter-Mountain, we believe that we will be able to meet our working capital and capital expenditure requirements through the second quarter of 2015.  However, we cannot be sure that our anticipated revenue growth will be realized or that we will generate significant positive cash flow from operations.  Moreover, we may not be able to raise sufficient additional capital on acceptable returns, or at all, to continue operations and may not be able to execute any strategic transactions.  Therefore, we are unable to assert that our financial position is sufficient to fund operations beyond the second quarter of 2015, and as a result, there is substantial doubt about our ability to continue as a going concern beyond the second quarter of 2015.

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2015
SEGMENT INFORMATION [Abstract]
Revenues per geographic area	Revenues per geographic area for the three months ended March 31 are summarized as follows:
	Revenues		2015				%				2014		%
	Domestic		$	6,802				2	%		$	9,672		9	%
	International			287,846				98	%			92,308		91	%
	Total		$	294,648				100	%		$	101,980		100	%
Customers with greater than 10% of total sales	A significant portion of our revenues are derived from a few major customers.  Customers with greater than 10% of total revenues for the three months ended March 31 are represented on the following table:
	Customers	Product		2015				2014
	Customer A	Altrazeal®			93	%			1	%
	Customer B	Altrazeal®			2	%			81	%
	Total				95	%			82	%

INVENTORY_Tables

INVENTORY (Tables)	3 Months Ended
	Mar. 31, 2015
INVENTORY [Abstract]
Components of inventory	The components of inventory, at the different stages of production, consisted of the following at March 31, 2015 and December 31, 2014:
	Inventory	31-Mar-15		31-Dec-14
	Raw materials	$	43,633	$	41,648
	Work-in-progress		310,648		271,571
	Finished goods		11,523		12,438
	Total	$	365,804	$	325,657

PROPERTY_EQUIPMENT_and_LEASEHO1

PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS (Tables)	3 Months Ended
	Mar. 31, 2015
PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS [Abstract]
Property, equipment and leasehold improvements	Property, equipment and leasehold improvements, net, consisted of the following at March 31, 2015 and December 31, 2014:
	Property, equipment and leasehold improvements	31-Mar-15			31-Dec-14
	Laboratory equipment	$	424,888		$	424,888
	Manufacturing equipment		1,599,894			1,599,894
	Computers, office equipment, and furniture		153,078			153,078
	Computer software		4,108			4,108
	Leasehold improvements		95,841			95,841
			2,277,809			2,277,809
	Less: accumulated depreciation and amortization		(1,904,008	)		(1,845,699	)
	Property, equipment and leasehold improvements, net	$	373,801		$	432,110

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2015
INTANGIBLE ASSETS [Abstract]
Intangible assets	Intangible assets are comprised of patents acquired in October, 2005.  Intangible assets, net consisted of the following at March 31, 2015 and December 31, 2014:
	Intangible assets	31-Mar-15			31-Dec-14
	Patent - Amlexanox (Aphthasol®)	$	2,090,000		$	2,090,000
	Patent - Amlexanox (OraDisc™ A)		6,873,080			6,873,080
	Patent - OraDisc™		73,000			73,000
	Patent - Hydrogel nanoparticle aggregate		589,858			589,858
			9,625,938			9,625,938
	Less: accumulated amortization		( 6,547,410	)		(6,430,249	)
	Intangible assets, net	$	3,078,528		$	3,195,689
Future aggregate amortization expense for intangible assets	The future aggregate amortization expense for intangible assets, remaining as of March 31, 2015, is as follows:
	Calendar Years	Future Amortization
		Expense
	2015 (Nine months)	$	357,987
	2016		476,450
	2017		475,148
	2018		475,148
	2019		475,148
	2020 & Beyond		818,647
	Total	$	3,078,528

INVESTMENTS_IN_UNCONSOLIDATED_1

INVESTMENTS IN UNCONSOLIDATED ENTITIES (Tables)	3 Months Ended
	Mar. 31, 2015
Altrazeal Trading Ltd. [Member]
Schedule of Equity Method Investments [Line Items]
Summarized financial information for investment	Summarized financial information for our investment in Altrazeal Trading Ltd. assuming 100% ownership is as follows:
	Altrazeal Trading Ltd.	31-Dec-12
	Balance sheet
	Total assets	$	136,661
	Total liabilities	$	660,006
	Total stockholders’ (deficit)	$	(523,345	)
	Statement of operations
	Revenues	$	61,028
	Net (loss)	$	(516,829	)
Altrazeal Trading GmbH [Member]
Schedule of Equity Method Investments [Line Items]
Summarized financial information for investment	Summarized financial information for our investment in Altrazeal Trading GmbH assuming 100% ownership is as follows:
	Altrazeal Trading GmbH	31-Dec-13
		(Unaudited)
	Balance sheet
	Total assets	$	757,784
	Total liabilities	$	1,563,046
	Total stockholders’ (deficit)	$	(805,262	)
	Statement of operations
	Revenues	$	---
	Net (loss)	$	(798,009	)
ORADISC GmbH [Member]
Schedule of Equity Method Investments [Line Items]
Summarized financial information for investment	Summarized financial information for our investment in ORADISC GmbH assuming 100% ownership is as follows:
	ORADISC GmbH	31-Dec-13
		(Unaudited)
	Balance sheet
	Total assets	$	305,069
	Total liabilities	$	302,572
	Total stockholders’ equity	$	2,497
	Statement of operations
	Revenues	$	---
	Net (loss)	$	(34,671	)

ACCRUED_LIABILITIES_Tables

ACCRUED LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2015
ACCRUED LIABILITIES [Abstract]
Accrued liabilities	Accrued liabilities consisted of the following at March 31, 2015 and December 31, 2014:
	Accrued Liabilities	31-Mar-15		31-Dec-14
	Accrued taxes – payroll	$	106,299	$	106,299
	Accrued compensation/benefits		123,887		96,795
	Accrued insurance payable		26,270		69,815
	Accrued property taxes		3,000		---
	Product rebates/returns		5		13
	Other		---		279
	Total accrued liabilities	$	259,461	$	273,201

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2015
STOCKHOLDERS' EQUITY [Abstract]
Warrants outstanding and number of shares of common stock subject to exercise	The following table summarizes the warrants outstanding and the number of shares of Common Stock subject to exercise as of March 31, 2015 and the changes therein during the three months then ended:
			Number of Shares of Common Stock Subject to Exercise			Weighted – Average
						Exercise Price
	Balance as of December 31, 2014			1,676,401		$	1.14
	Warrants issued (1)			(31,341	)	$	0.35
	Warrants exercised			---			---
	Warrants cancelled			---			---
	Balance as of March 31, 2015			1,645,060		$	1.15
	-1	As part of the June 2012 Note, Inter-Mountain received a total of seven warrants to purchase, if they all had vested, an aggregate of 3,142,857 shares of Common Stock, which number of shares could increase based upon the terms and conditions of the warrants.  The warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017.  Warrants for 785,714, 392,857, 392,857, and 392,857 shares of Common Stock vested on June 27, 2012, December 31, 2012, February 26, 2013, and July 15, 2013, respectively, and three warrants for 1,571,428 shares of Common Stock were exercised in 2013.  On January 22, 2014, we elected to offset and deduct the three remaining Investor Notes from the principle amount due to Inter-Mountain under the June 2012 Note and as a result of the offset and deduction the three remaining warrants terminated.  On April 14, 2015, we reached agreement with Inter-Mountain that 361,516 shares of Common Stock will be issued upon the exercise of the one unexercised warrant (originally included in this Table as 392,857 shares, which was based upon an exercise price of $0.35 per share of Common Stock).
Expiration dates for warrants subject to exercise	Of the warrant shares subject to exercise as of March 31, 2015, expiration of the right to exercise is as follows:
	Date of Expiration		Number of Warrant Shares of Common Stock Subject to Expiration
	May 15, 2015			357,155
	June 13, 2016			35,000
	July 16, 2016			116,667
	July 28, 2016			34,722
	June 27, 2017			361,516
	March 14, 2018			660,000
	January 15, 2019			80,000
	Total			1,645,060

EARNINGS_PER_SHARE_Tables

EARNINGS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2015
EARNINGS PER SHARE [Abstract]
Common shares excluded from calculating basic and diluted net loss per common share	Shares used in calculating basic and diluted net loss per common share exclude these potential common shares as of March 31, 2015 and December 31, 2014:
		31-Mar-15		31-Dec-14
	Warrants to purchase Common Stock		1,645,060		1,676,401
	Stock options to purchase common stock		1,699,907		1,699,907
	Total		3,344,967		3,376,308

SHARE_BASED_COMPENSATION_Table

SHARE BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2015
SHARE BASED COMPENSATION [Abstract]
Stock option awards granted	Our Board granted the following incentive stock option awards to executives or employees and nonstatutory stock option awards to directors or non-employees for the three months ended March 31:
			Three Months Ended March 31,
			2015 (1)				2014 (1)
	Incentive Stock Options
	Quantity			---				---
	Weighted average fair value per share			---				---
	Fair value			---				---
	Nonstatutory Stock Options
	Quantity			---				---
	Weighted average fair value per share			---				---
	Fair value			---				---
	-1	The Company did not award any shared-based compensation for the three months ended March 31, 2015 and 2014.
Allocated share-based compensation expense	The following table summarizes share-based compensation related to stock options for the three months ended March 31:
			Three Months Ended
			March 31,
			2015				2014
	Research and development		$	18,612			$	5,307
	Selling, general and administrative			56,736				19,233
	Total share-based compensation expense		$	75,348			$	24,540
Stock option activity	The following table summarizes the stock options outstanding and the number of shares of Common Stock subject to exercise as of March 31, 2015 and the changes therein during the three months then ended:
			Stock Options				Weighted Average Exercise Price per Share
	Outstanding as of December 31, 2014			1,699,907			$	1.73
	Granted			---				---
	Forfeited/cancelled			---				---
	Exercised			---				---
	Outstanding as of March 31, 2015			1,699,907			$	1.73
Stock option grants outstanding and exercisable	The following table presents the stock option grants outstanding and exercisable as of March 31, 2015:
	Options Outstanding										Options Exercisable
	Stock Options Outstanding				Weighted Average Exercise Price per Share				Weighted Average Remaining Contractual Life in Years		Stock Options Exercisable		Weighted Average Exercise Price per Share
		892,500			$	0.33				8		645,000	$	0.33
		685,000				1.15				7.7		77,500		1.15
		53,334				2.38				3.2		53,334		2.38
		69,073				25.12				2.3		69,073		25.12
		1,699,907			$	1.73				7.5		844,907	$	2.56

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Mar. 31, 2015
COMMITMENTS AND CONTINGENCIES [Abstract]
Future minimum lease payments	The future minimum lease payments under the 2015 office lease and the 2015 equipment lease are as follows as of March 31, 2015:
	Calendar Years		Future Lease Expense
	2015 (Nine months)		$	89,880
	2016			119,840
	2017			119,840
	2018			28,858
	2019			---
	Total		$	358,418
Summary of compensation earned, compensation paid in cash, and compensation temporarily deferred	As of March 31, 2015, the following table summarizes the compensation temporarily deferred and subsequent repayments:
	Name		2015		2014			2013			2012		2011		Total
	Kerry P. Gray (1) (2) (3)		$	57,575	$	(119,986	)	$	(91,000	)	$	220,673	$	140,313	$	207,575
	Terrance K. Wallberg			6,633		(25,000	)		(35,769	)		24,230		36,539		6,633
	Total		$	64,208	$	(144,986	)	$	(126,769	)	$	244,903	$	176,852	$	214,208
		-1	During 2015, Mr. Gray temporarily deferred compensation of $57,575 which consisted of $5,075 earned as salary compensation for his duties as President of the Company and $52,500 for his duties as Chairman of the Executive Committee of the Company’s Board of Directors.
		-2	During 2014, Mr. Gray temporarily deferred compensation of $150,000 which consisted of $62,500 earned as salary compensation for his duties as President of the Company and $87,500 for his duties as Chairman of the Executive Committee of the Company’s Board of Directors.  During 2014, Mr. Gray was also repaid $269,986 of temporarily deferred compensation, of which $100,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.
		-3	During 2013, Mr. Gray temporarily deferred compensation of $221,500 which consisted of $11,500 earned pursuant to a Separation Agreement and $210,000 for his duties as Chairman of the Executive Committee of the Company’s Board of Directors.  During 2013, Mr. Gray was also repaid $312,500 of temporarily deferred compensation, of which $300,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.

COMPANY_OVERVIEW_AND_BASIS_OF_2

COMPANY OVERVIEW AND BASIS OF PRESENTATION (Details) (Inter-Mountain [Member], Subsequent Event [Member], USD $)	1 Months Ended
	Apr. 30, 2015
Inter-Mountain [Member] | Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Proceeds from issuance of debt	$500,000

SEGMENT_INFORMATION_Details

SEGMENT INFORMATION (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
	Licensee
	Segment
SEGMENT INFORMATION [Abstract]
Number of business segments	1
Number of international licensees	7
Revenues per geographic area [Abstract]
Total Revenues	$294,648	$101,980
Total revenue, percentage (in hundredths)	100.00%	100.00%
Revenue, Major Customer [Line Items]
Sales from major customer, percentage (in hundredths)	95.00%	82.00%
Customer A [Member] | Altrazeal [Member]
Revenue, Major Customer [Line Items]
Sales from major customer, percentage (in hundredths)	93.00%	1.00%
Customer B [Member] | Altrazeal [Member]
Revenue, Major Customer [Line Items]
Sales from major customer, percentage (in hundredths)	2.00%	81.00%
Reportable Geographical Components [Member] | Domestic [Member]
Revenues per geographic area [Abstract]
Total Revenues	6,802	9,672
Total revenue, percentage (in hundredths)	2.00%	9.00%
Reportable Geographical Components [Member] | International [Member]
Revenues per geographic area [Abstract]
Total Revenues	$287,846	$92,308
Total revenue, percentage (in hundredths)	98.00%	91.00%

INVENTORY_Details

INVENTORY (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Components of inventory [Abstract]
Raw materials	$43,633	$41,648
Work-in-progress	310,648	271,571
Finished goods	11,523	12,438
Total	$365,804	$325,657

PROPERTY_EQUIPMENT_and_LEASEHO2

PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Property, equipment and leasehold improvements, net [Abstract]
Property, equipment and leasehold improvements, gross	$2,277,809		$2,277,809
Less: accumulated depreciation and amortization	-1,904,008		-1,845,699
Property, equipment and leasehold improvements, net	373,801		432,110
Depreciation expense	58,309	60,554
Laboratory Equipment [Member]
Property, equipment and leasehold improvements, net [Abstract]
Property, equipment and leasehold improvements, gross	424,888		424,888
Manufacturing Equipment [Member]
Property, equipment and leasehold improvements, net [Abstract]
Property, equipment and leasehold improvements, gross	1,599,894		1,599,894
Computers, Office Equipment, and Furniture [Member]
Property, equipment and leasehold improvements, net [Abstract]
Property, equipment and leasehold improvements, gross	153,078		153,078
Computer Software [Member]
Property, equipment and leasehold improvements, net [Abstract]
Property, equipment and leasehold improvements, gross	4,108		4,108
Leasehold Improvements [Member]
Property, equipment and leasehold improvements, net [Abstract]
Property, equipment and leasehold improvements, gross	$95,841		$95,841

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$9,625,938		$9,625,938
Less: accumulated amortization	-6,547,410		-6,430,249
Intangible assets, net	3,078,528		3,195,689
Amortization expense	117,161	117,161
Future aggregate amortization expense for intangible assets [Abstract]
2015 (Nine months)	357,987
2016	476,450
2017	475,148
2018	475,148
2019	475,148
2020 & Beyond	818,647
Total	3,078,528
Patents [Member] | Amlexanox (Aphthasol) [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	2,090,000		2,090,000
Patents [Member] | Amlexanox (OraDiscA) [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	6,873,080		6,873,080
Patents [Member] | ORADISC [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	73,000		73,000
Patents [Member] | Hydrogel Nanoparticle Aggregate [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$589,858		$589,858

INVESTMENTS_IN_UNCONSOLIDATED_2

INVESTMENTS IN UNCONSOLIDATED ENTITIES (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2012	Dec. 31, 2013
Statement of operations [Abstract]
Gains losses on equity method investments	$0	$0
Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Percentage of noncontrolling interest (in hundredths)	20.00%
Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Percentage of noncontrolling interest (in hundredths)	50.00%
Altrazeal Trading Ltd. [Member]
Schedule of Equity Method Investments [Line Items]
Non-dilutable ownership interest (in hundredths)			25.00%
Unrecorded profit (loss)			129,207
Balance sheet [Abstract]
Total assets			136,661
Total liabilities			660,006
Total stockholders' equity (deficit)			-523,345
Statement of operations [Abstract]
Revenues			61,028
Net (loss)			-516,829
ORADISC GmbH [Member]
Schedule of Equity Method Investments [Line Items]
Non-dilutable ownership interest (in hundredths)				25.00%
Unrecorded profit (loss)				11,430
Balance sheet [Abstract]
Total assets				305,069
Total liabilities				302,572
Total stockholders' equity (deficit)				2,497
Statement of operations [Abstract]
Revenues				0
Net (loss)				-34,671
Altrazeal Trading GmbH [Member]
Schedule of Equity Method Investments [Line Items]
Non-dilutable ownership interest (in hundredths)				25.00%
Unrecorded profit (loss)				213,370
Balance sheet [Abstract]
Total assets				757,784
Total liabilities				1,563,046
Total stockholders' equity (deficit)				-805,262
Statement of operations [Abstract]
Revenues				0
Net (loss)				($798,009)
Altrazeal AG [Member]
Schedule of Equity Method Investments [Line Items]
Non-dilutable ownership interest (in hundredths)	25.00%

ACCRUED_LIABILITIES_Details

ACCRUED LIABILITIES (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Accrued liabilities [Abstract]
Accrued taxes - payroll	$106,299	$106,299
Accrued compensation/benefits	123,887	96,795
Accrued insurance payable	26,270	69,815
Accrued property taxes	3,000	0
Product rebates/returns	5	13
Other	0	279
Total accrued liabilities	$259,461	$273,201

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (USD $)	3 Months Ended		12 Months Ended	0 Months Ended
	Mar. 31, 2015		Dec. 31, 2013	Jan. 22, 2014	Dec. 31, 2014	Dec. 31, 2012	Jul. 15, 2013	Feb. 26, 2013	Jun. 27, 2012
			Warrant	Warrant
Common Stock [Abstract]
Common Stock, shares issued (in shares)	24,458,018				24,458,018
Common Stock, shares outstanding (in shares)	24,458,018				24,458,018
Common stock issued during period (in shares)	0
Warrants and Number of Shares of Common Stock Subject to Exercise [Roll Forward]
Balance (in shares)	1,676,401
Warrants issued (in shares)	-31,341	[1]
Warrants exercised (in shares)	0
Warrants cancelled (in shares)	0
Balance (in shares)	1,645,060
Warrants, Weighted-Average Exercise Price [Abstract]
Balance (in dollars per share)	$1.14
Warrants issued (in dollars per share)	$0.35	[1]
Warrants exercised (in dollars per share)	$0
Warrants cancelled (in dollars per share)	$0
Balance (in dollars per share)	$1.15
Warrant shares subject to expiration [Abstract]
Number of Warrant Shares of Common Stock Subject to Expiration (in shares)	1,645,060
Exercise price of warrants (in dollars per share)	$0.35
Common stock vested upon initial warrant (in shares)	1,645,060
Inter-Mountain [Member]
Warrant shares subject to expiration [Abstract]
Number of warrants to purchase common stock (in shares)						7
Aggregate shares of common stock issued upon exercise of warrants (in shares)			1,571,428			3,142,857
Number of warrants exercised (in shares)			3
Exercise price of warrants (in dollars per share)						$0.35
Warrant - June 2012 Debt Offering [Member] | Private Placement [Member]
Warrants and Number of Shares of Common Stock Subject to Exercise [Roll Forward]
Balance (in shares)						392,857	392,857	392,857	785,714
Balance (in shares)	392,857					392,857	392,857	392,857	785,714
Warrant shares subject to expiration [Abstract]
Number of Warrant Shares of Common Stock Subject to Expiration (in shares)	392,857					392,857	392,857	392,857	785,714
Number of unexercised warrants (in shares)	1
Common stock vested upon initial warrant (in shares)	392,857					392,857	392,857	392,857	785,714
Warrant - June 2012 Debt Offering [Member] | Inter-Mountain [Member]
Warrant shares subject to expiration [Abstract]
Number of warrants terminated (in shares)				3
May 15, 2015 [Member]
Warrants and Number of Shares of Common Stock Subject to Exercise [Roll Forward]
Balance (in shares)	357,155
Warrant shares subject to expiration [Abstract]
Number of Warrant Shares of Common Stock Subject to Expiration (in shares)	357,155
Common stock vested upon initial warrant (in shares)	357,155
June 13, 2016 [Member]
Warrants and Number of Shares of Common Stock Subject to Exercise [Roll Forward]
Balance (in shares)	35,000
Warrant shares subject to expiration [Abstract]
Number of Warrant Shares of Common Stock Subject to Expiration (in shares)	35,000
Common stock vested upon initial warrant (in shares)	35,000
July 16, 2016 [Member]
Warrants and Number of Shares of Common Stock Subject to Exercise [Roll Forward]
Balance (in shares)	116,667
Warrant shares subject to expiration [Abstract]
Number of Warrant Shares of Common Stock Subject to Expiration (in shares)	116,667
Common stock vested upon initial warrant (in shares)	116,667
July 28, 2016 [Member]
Warrants and Number of Shares of Common Stock Subject to Exercise [Roll Forward]
Balance (in shares)	34,722
Warrant shares subject to expiration [Abstract]
Number of Warrant Shares of Common Stock Subject to Expiration (in shares)	34,722
Common stock vested upon initial warrant (in shares)	34,722
June 27, 2017 [Member]
Warrants and Number of Shares of Common Stock Subject to Exercise [Roll Forward]
Balance (in shares)	361,516
Warrant shares subject to expiration [Abstract]
Number of Warrant Shares of Common Stock Subject to Expiration (in shares)	361,516
Common stock vested upon initial warrant (in shares)	361,516
March 14, 2018 [Member]
Warrants and Number of Shares of Common Stock Subject to Exercise [Roll Forward]
Balance (in shares)	660,000
Warrant shares subject to expiration [Abstract]
Number of Warrant Shares of Common Stock Subject to Expiration (in shares)	660,000
Common stock vested upon initial warrant (in shares)	660,000
January 15, 2019 [Member]
Warrants and Number of Shares of Common Stock Subject to Exercise [Roll Forward]
Balance (in shares)	80,000
Warrant shares subject to expiration [Abstract]
Number of Warrant Shares of Common Stock Subject to Expiration (in shares)	80,000
Common stock vested upon initial warrant (in shares)	80,000
Series A Preferred Stock [Member]
Preferred Stock [Abstract]
Preferred stock, shares issued (in shares)	0
Preferred stock, shares outstanding (in shares)	0
[1]	As part of the June 2012 Note, Inter-Mountain received a total of seven warrants to purchase, if they all had vested, an aggregate of 3,142,857 shares of Common Stock, which number of shares could increase based upon the terms and conditions of the warrants. The warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017. Warrants for 785,714, 392,857, 392,857, and 392,857 shares of Common Stock vested on June 27, 2012, December 31, 2012, February 26, 2013, and July 15, 2013, respectively, and three warrants for 1,571,428 shares of Common Stock were exercised in 2013. On January 22, 2014, we elected to offset and deduct the three remaining Investor Notes from the principle amount due to Inter-Mountain under the June 2012 Note and as a result of the offset and deduction the three remaining warrants terminated. On April 14, 2015, we reached agreement with Inter-Mountain that 361,516 shares of Common Stock will be issued upon the exercise of the one unexercised warrant (originally included in this Table as 392,857 shares, which was based upon an exercise price of $0.35 per share of Common Stock).

EARNINGS_PER_SHARE_Details

EARNINGS PER SHARE (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from calculating basic and diluted net loss per common share (in shares)	3,344,967	3,376,308
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from calculating basic and diluted net loss per common share (in shares)	1,645,060	1,676,401
Stock options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from calculating basic and diluted net loss per common share (in shares)	1,699,907	1,699,907

SHARE_BASED_COMPENSATION_Detai

SHARE BASED COMPENSATION (Details) (USD $)	0 Months Ended						3 Months Ended
	Jun. 13, 2014	Jun. 05, 2014	Jun. 14, 2012	Jun. 15, 2010	Dec. 17, 2009	8-May-07	Mar. 31, 2015		Mar. 31, 2014		Mar. 31, 2006
Additional disclosures [Abstract]
Number of shares authorized (in shares)							2,800,000
Number of additional shares authorized (in shares)	600,000	1,000,000	400,000	200,000	200,000	266,667
Incentive Stock Options [Member]
Options Granted [Abstract]
Quantity (in shares)							0	[1]	0	[1]
Weighted average fair value per share (in dollars per share)							$0	[1]	$0	[1]
Fair value							$0	[1]	$0	[1]
Options, Outstanding [Roll Forward]
Granted (in shares)							0	[1]	0	[1]
Nonstatutory Stock Options [Member]
Options Granted [Abstract]
Quantity (in shares)							0	[1]	0	[1]
Weighted average fair value per share (in dollars per share)							$0	[1]	$0	[1]
Fair value							0	[1]	0	[1]
Options, Outstanding [Roll Forward]
Granted (in shares)							0	[1]	0	[1]
Stock Options [Member]
Options Granted [Abstract]
Quantity (in shares)							0
Options, Outstanding [Roll Forward]
Outstanding, beginning of period (in shares)							1,699,907
Granted (in shares)							0
Forfeited/cancelled (in shares)							0
Exercised (in shares)							0
Outstanding, end of period (in shares)							1,699,907
Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)							$1.73
Granted (in dollars per share)							$0
Forfeited/cancelled (in dollars per share)							$0
Exercised (in dollars per share)							$0
Outstanding, end of period (in dollars per share)							$1.73
Nonvested Awards, unearned share-based compensation [Abstract]
Unearned share-based compensation expense							$482,000
Unearned share-based compensation, recognition period							30 months
Restricted Stock [Member]
Additional disclosures [Abstract]
Granted (in shares)							0		0
Restricted Stock [Member] | Minimum [Member]
Additional disclosures [Abstract]
Vesting period							2 years
Restricted Stock [Member] | Maximum [Member]
Additional disclosures [Abstract]
Vesting period							5 years
Contractual term							10 years
2006 Equity Incentive Plan [Member]
Additional disclosures [Abstract]
Number of shares authorized (in shares)											133,333
Number of shares available for grant (in shares)							1,030,647
2006 Equity Incentive Plan [Member] | Stock Options [Member]
Additional disclosures [Abstract]
Number of options granted to date (in shares)							2,061,167
2006 Equity Incentive Plan [Member] | Stock Options [Member] | Minimum [Member]
Additional disclosures [Abstract]
Vesting period							1 year
2006 Equity Incentive Plan [Member] | Stock Options [Member] | Maximum [Member]
Additional disclosures [Abstract]
Vesting period							4 years
2006 Equity Incentive Plan [Member] | Restricted Stock [Member]
Additional disclosures [Abstract]
Number of restricted shares granted to date (in shares)							68,616
2006 Equity Incentive Plan [Member] | Restricted Stock [Member] | Minimum [Member]
Additional disclosures [Abstract]
Vesting period							6 months
2006 Equity Incentive Plan [Member] | Restricted Stock [Member] | Maximum [Member]
Additional disclosures [Abstract]
Vesting period							5 years
[1]	The Company did not award any shared-based compensation for the three months ended March 31, 2015 and 2014.

SHARE_BASED_COMPENSATION_Alloc

SHARE BASED COMPENSATION, Allocated Compensation expense (Details) (Stock Options [Member], USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$75,348	$24,540
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	18,612	5,307
Selling, General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$56,736	$19,233

SHARE_BASED_COMPENSATION_Stock

SHARE BASED COMPENSATION, Stock options grant outstanding and exercisable (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Outstanding (in shares)	1,699,907
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$1.73
Options Outstanding, Weighted Average Remaining Contractual Life in Years	7 years 6 months
Stock Options Exercisable (in shares)	844,907
Options Exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$2.56
Exercise Price Range 1 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Outstanding (in shares)	892,500
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$0.33
Options Outstanding, Weighted Average Remaining Contractual Life in Years	8 years
Stock Options Exercisable (in shares)	645,000
Options Exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$0.33
Exercise Price Range 2 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Outstanding (in shares)	685,000
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$1.15
Options Outstanding, Weighted Average Remaining Contractual Life in Years	7 years 8 months 12 days
Stock Options Exercisable (in shares)	77,500
Options Exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$1.15
Exercise Price Range 3 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Outstanding (in shares)	53,334
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$2.38
Options Outstanding, Weighted Average Remaining Contractual Life in Years	3 years 2 months 12 days
Stock Options Exercisable (in shares)	53,334
Options Exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$2.38
Exercise Price Range 4 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Outstanding (in shares)	69,073
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$25.12
Options Outstanding, Weighted Average Remaining Contractual Life in Years	2 years 3 months 18 days
Stock Options Exercisable (in shares)	69,073
Options Exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$25.12

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	3 Months Ended										12 Months Ended	0 Months Ended	24 Months Ended	60 Months Ended	36 Months Ended
	Mar. 31, 2015		Mar. 31, 2014		Mar. 31, 2013		Mar. 31, 2012		Mar. 31, 2011		Dec. 31, 2014	Mar. 17, 2015	Mar. 31, 2013	Mar. 31, 2011	Feb. 01, 2018	Mar. 07, 2008
Future minimum lease payments [Abstract]
2015 (Nine months)	$89,880
2016	119,840
2017	119,840
2018	28,858
2019	0
Total	358,418
Rent expense for operating lease	31,165		30,380
Related Party Obligations [Abstract]
Outstanding accounts receivable	978,676										798,147
Concentration risk, percentage (in hundredths)	95.00%		82.00%
Summary of compensation earned, compensation paid in cash, and compensation temporarily deferred [Abstract]
Deferred compensation liability	64,208		-144,986		-126,769		244,903		176,852
Deferred compensation	214,208										150,000
Compensation accounts payable	140,000										87,500
Compensation accrued liabilities	74,208										62,500
Milestone payments [Line Items]
Future milestone obligations	4,750,000
Access Pharmaceuticals [Member] | Annual Sales, Certain Products [Member] | Minimum [Member]
Milestone payments [Line Items]
Milestone for payment	20,000,000
Access Pharmaceuticals [Member] | Annual Sales, Certain Products [Member] | Maximum [Member]
Milestone payments [Line Items]
Milestone for payment	40,000,000
Access Pharmaceuticals [Member] | Annual Sales, Any One Certain Product [Member]
Milestone payments [Line Items]
Milestone for payment	20,000,000
Access Pharmaceuticals [Member] | Cumulative Sales, Certain Products [Member] | Minimum [Member]
Milestone payments [Line Items]
Milestone for payment	50,000,000
Access Pharmaceuticals [Member] | Cumulative Sales, Certain Products [Member] | Maximum [Member]
Milestone payments [Line Items]
Milestone for payment	100,000,000
ProStrakan Ltd [Member]
Milestone payments [Line Items]
Royalty percentage (in hundredths)																30.00%
ProStrakan Ltd [Member] | Maximum [Member]
Milestone payments [Line Items]
Future milestone obligations																1,400,000
Kerry P. Gray [Member]
Summary of compensation earned, compensation paid in cash, and compensation temporarily deferred [Abstract]
Deferred compensation liability	57,575	[1],[2],[3]	-119,986	[1],[2],[3]	-91,000	[1],[2],[3]	220,673	[1],[2],[3]	140,313	[1],[2],[3]
Deferred compensation	207,575	[1],[2],[3]	150,000		221,500								221,500
Deferred compensation liability pursuant to separation agreement					11,500
Deferred compensation liability pursuant to duties as president	5,075		62,500
Deferred compensation liability pursuant to duties as chairman	52,500		87,500		210,000
Repayment of temporarily deferred compensation			269,986		312,500
Proceeds from issuance of common stock under March 2013 offering			100,000		300,000
Terrance K. Wallberg [Member]
Summary of compensation earned, compensation paid in cash, and compensation temporarily deferred [Abstract]
Deferred compensation liability	6,633		-25,000		-35,769		24,230		36,539
Deferred compensation	6,633
Altrazeal Trading Ltd. [Member]
Related Party Obligations [Abstract]
Related party sales	282,000		86,000
Outstanding accounts receivable	979,000										798,000
Altrazeal Trading Ltd. [Member] | Sales Revenue, Goods, Net [Member]
Related Party Obligations [Abstract]
Concentration risk, percentage (in hundredths)	96.00%		84.00%
Altrazeal Trading Ltd. [Member] | Accounts Receivable [Member]
Related Party Obligations [Abstract]
Concentration risk, percentage (in hundredths)	99.70%										99.50%
Office and Laboratory Space [Member]
Operating Leased Assets [Line Items]
Minimum monthly lease obligation			9,193									9,436	9,776	9,330
Future minimum monthly lease obligation after specified period	9,379
Office Equipment [Member]
Operating Leased Assets [Line Items]
Minimum monthly lease obligation	744
Office Equipment [Member] | Subsequent Event [Member]
Operating Leased Assets [Line Items]
Minimum monthly lease obligation															$551
[1]	During 2015, Mr. Gray temporarily deferred compensation of $57,575 which consisted of $5,075 earned as salary compensation for his duties as President of the Company and $52,500 for his duties as Chairman of the Executive Committee of the Company's Board of Directors.
[2]	During 2014, Mr. Gray temporarily deferred compensation of $150,000 which consisted of $62,500 earned as salary compensation for his duties as President of the Company and $87,500 for his duties as Chairman of the Executive Committee of the Company's Board of Directors. During 2014, Mr. Gray was also repaid $269,986 of temporarily deferred compensation, of which $100,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.
[3]	During 2013, Mr. Gray temporarily deferred compensation of $221,500 which consisted of $11,500 earned pursuant to a Separation Agreement and $210,000 for his duties as Chairman of the Executive Committee of the Company's Board of Directors. During 2013, Mr. Gray was also repaid $312,500 of temporarily deferred compensation, of which $300,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.

LEGAL_PROCEEDINGS_Details

LEGAL PROCEEDINGS (Details)	3 Months Ended
	Mar. 31, 2015	Apr. 15, 2015
Loss Contingencies [Line Items]
Number of shares under non-standard cashless exercise (in shares)	782,284
Number of shares exercisable on cashless basis (in shares)	261,516
Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of common shares issued on exercise of warrants (in shares)		361,516

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details)

Mar. 31, 2015

Dec. 31, 2014

Mar. 31, 2015

Apr. 15, 2015

Apr. 15, 2015

Mar. 31, 2015

Apr. 15, 2015

Apr. 15, 2015

Apr. 15, 2015

Apr. 15, 2015

Dec. 31, 2015

Oct. 31, 2015

Aug. 31, 2015

Jun. 30, 2015

12-May-15

12-May-15

Sep. 30, 2015

12-May-15

12-May-15

USD ($)

USD ($)

Altrazeal Trading GmbH [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Inter Mountain Capital Corp [Member]

Inter Mountain Capital Corp [Member]

Inter Mountain Capital Corp [Member]

Inter Mountain Capital Corp [Member]

Inter Mountain Capital Corp [Member]

Inter Mountain Capital Corp [Member]

Altrazeal Trading GmbH [Member]

Altrazeal Trading GmbH [Member]

Altrazeal Trading GmbH [Member]

Altrazeal Trading GmbH [Member]

Altrazeal Trading GmbH [Member]

Altrazeal Trading GmbH [Member]

Altrazeal Trading GmbH [Member]

Altrazeal Trading GmbH [Member]

Altrazeal Trading GmbH [Member]

USD ($)

USD ($)

Conversion Condition One [Member]

Conversion Condition Two [Member]

Conversion Condition Two [Member]

EUR (€)

EUR (€)

EUR (€)

EUR (€)

USD ($)

EUR (€)

EUR (€)

EUR (€)

Maximum [Member]

USD ($)

Installment

Subsequent Event [Line Items]

Proceeds from issuance of promissory note

$550,000

Promissory note original issue discount

50,000

Purchase price for promissory note

500,000

Interest rate on promissory note (in hundredths)

10.00%

Promissory note monthly installment payments

45,000

Monthly installment payments commencing period

120 days

Common stock par value ( in dollars per share)

$0.00

$0.00

$0.00

Weighted average price of common stock (in dollars per share)

$0.05

Average percentage of three lowest volume weighted average price (in hundredths)

80.00%

70.00%

Number of trading days in conversion

20 days

20 days

Notes prepayment percentage (in hundredths)

120.00%

Notes repayment default amount

100,000

Judgement stay period on note default

30 days

Increase in interest rate (in hundredths)

18.00%

Warrant to purchase shares of common stock (in shares)

361,516

194,118

Warrants exercise price (in dollars per share)

$0.35

$0.85

Warrants expiration date

30-Apr-20

Maximum Number Of Days With In Which Registration Statement Should Be Declared

120 days

Number of days for registration effective for a period

180 days

Percentage of voting interest acquired (in hundreds)

25.00%

75.00%

Purchase price allocation, share capital

3,150,000

Purchase price allocation, product inventory

88,834

Purchase price of acquisition, installment amount

1,147,200

Purchase price offset of accounts receivable amount

646,500

Number of installments

4

4

Purchase price of share capital, installment amount

500,700

500,700

500,700

500,700

Percentage of equity being transferred on each installment (in hundredths)

15.00%

15.00%

Percentage of average closing price of shares (in hundredths)

110.00%

110.00%

Number of trading days

10 days

10 days

Percentage of warrants included in installment payment (in hundredths)

10.00%

10.00%

Premium per share included in installment payments (in dollars per share)

$0.30

Payment for inventory included in working capital

€ 88,834

Purchase agreement execution period

60 days